title: Preparation and characterization of nicotine-magnesium aluminum silicate complex-loaded sodium alginate matrix tablets for buccal delivery.
abstract: Nicotine (NCT) buccal tablets consisting of sodium alginate (SA) and nicotine-magnesium aluminum silicate (NCT-MAS) complexes acting as drug carriers were prepared using the direct compression method. The effects of the preparation pH levels of the NCT-MAS complexes and the complex/SA ratios on NCT release, permeation across mucosa, and mucoadhesive properties of the tablets were investigated. The NCT-MAS complex-loaded SA tablets had good physical properties and zero-order release kinetics of NCT, which indicate a swelling/erosion-controlled release mechanism. Measurement of unidirectional NCT release and permeation across porcine esophageal mucosa using a modified USP dissolution apparatus 2 showed that NCT delivery was controlled by the swollen gel matrix of the tablets. This matrix, which controlled drug diffusion, resulted from the molecular interactions of SA and MAS. Tablets containing the NCT-MAS complexes prepared at pH 9 showed remarkably higher NCT permeation rates than those containing the complexes prepared at acidic and neutral pH levels. Larger amounts of SA in the tablets decreased NCT release and permeation rates. Additionally, the presence of SA could enhance the mucoadhesive properties of the tablets. These findings suggest that SA plays the important role not only in controlling release and permeation of NCT but also for enhancing the mucoadhesive properties of the NCT-MAS complex-loaded SA tablets, and these tablets demonstrate a promising buccal delivery system for NCT.
authors: Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand.
authors: Sopaphan
authors: S
authors: Kanjanabat
authors: Thaned
authors: T
authors: Pongjanyakul
references: J Control Release. 2007 Sep 26;122(2):135-40
references: 17688966
references: J Control Release. 2014 Sep 28;190:31-2
references: 25356469
references: Adv Drug Deliv Rev. 2005 Nov 3;57(11):1666-91
references: 16183164
references: Eur J Pharm Sci. 2004 Jul;22(4):279-86
references: 15196584
references: J Control Release. 2000 Sep 3;68(3):405-12
references: 10974394
references: Int J Pharm. 2002 May 15;238(1-2):123-32
references: 11996816
references: Colloids Surf B Biointerfaces. 2009 Nov 1;74(1):103-13
references: 19643587
references: Int J Pharm. 1999 Jul 5;184(1):63-72
references: 10425352
references: Int J Pharm. 2008 Dec 8;364(2):328-43
references: 18822362
references: J Pharm Sci. 1997 Feb;86(2):257-62
references: 9040106
references: J Control Release. 2006 Aug 10;114(1):15-40
references: 16828915
references: Int J Pharm. 2002 Apr 26;237(1-2):215-26
references: 11955819
references: Arch Oral Biol. 2005 Dec;50(12):981-7
references: 15955526
references: J Control Release. 2002 Feb 19;79(1-3):243-54
references: 11853935
references: J Control Release. 2000 Sep 3;68(3):397-404
references: 10974393
references: J Pharm Pharmacol. 1994 Mar;46(3):192-5
references: 8027926
references: J Control Release. 2005 Oct 3;107(2):343-56
references: 16061302
references: Biol Pharm Bull. 1994 May;17(5):745-7
references: 7920448
references: Int J Pharm. 2004 Jun 11;277(1-2):173-8
references: 15158980
references: Eur J Pharm Sci. 2001 May;13(2):123-33
references: 11297896
references: Pharm Acta Helv. 1985;60(4):110-1
references: 4011621
references: Colloids Surf B Biointerfaces. 2010 Jun 1;77(2):227-33
references: 20188529
references: Int J Pharm. 2006 Mar 27;311(1-2):196-202
references: 16457974
references: Colloids Surf B Biointerfaces. 2008 Aug 1;65(1):54-60
references: 18395425
references: Int J Pharm. 2009 Jan 5;365(1-2):100-8
references: 18790031